Udca

# Udca ## Overview - **Classification**: Bile acid - **Mechanism**: Increases bile flow, reduces cholesterol saturation of bile, dissolves cholesterol gallstones, protects hepatocytes, and modulates immune responses in cholestatic liver diseases. ## Primary Indications 1. **Primary Biliary Cholangitis (PBC)** - Improves liver biochemical parameters and may delay disease progression. 2. **Cholesterol Gallstones** - Dissolves small to medium sized non-calcified gallstones in patients who cannot undergo surgery. 3. **Intrahepatic Cholestasis of Pregnancy (ICP)** - Alleviates pruritus and improves liver function tests. 4. **Cystic Fibrosis-Associated Liver Disease (CFALD)** - Improves liver function and bile flow in children and adults. ## Adult Dosing ### Standard Dosing **Primary Biliary Cholangitis (PBC)** - **Dose**: **13-15 mg/kg/day** - **Frequency**: Divided into **2-4 doses daily** - **Route**: Oral - **Duration**: Lifelong treatment - **Maximum**: **15 mg/kg/day** **Cholesterol Gallstones** - **Dose**: **8-10 mg/kg/day** - **Frequency**: Divided into **2-3 doses daily** - **Route**: Oral - **Duration**: Typically **6-24 months**, continued for 3 months after stone dissolution. - **Maximum**: **15 mg/kg/day** **Intrahepatic Cholestasis of Pregnancy (ICP)** - **Dose**: **10-15 mg/kg/day**, may increase up to **20 mg/kg/day** - **Frequency**: Divided into **2-3 doses daily** - **Route**: Oral - **Duration**: Until delivery **Cystic Fibrosis-Associated Liver Disease (CFALD)** - **Dose**: **20 mg/kg/day** - **Frequency**: Divided into **2-3 doses daily** - **Route**: Oral - **Maximum**: **20 mg/kg/day** ### Dose Adjustments - **Renal Impairment**: No specific adjustments, primarily hepatobiliary excretion. - **Hepatic Impairment**: No specific adjustments as it is used for hepatic conditions. Not recommended in decompensated cirrhosis. - **Elderly Patients**: No specific dose adjustments needed; initiate at lower end of dosing range. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Off-label for cholestasis/biliary atresia (pre-Kasai) - **Dose**: **10-30 mg/kg/day** - **Frequency**: Divided into **2-3 doses daily** - **Maximum**: Clinical judgment, usually **30 mg/kg/day** - **Special Notes**: Use oral suspension; monitor liver function closely. ### Infants (1-12 months) - **Indication**: Off-label for cholestasis/CFALD - **Dose**: **10-30 mg/kg/day** - **Frequency**: Divided into **2-3 doses daily** - **Maximum**: Clinical judgment, typically **30 mg/kg/day** for cholestasis, **20 mg/kg/day** for CFALD. ### Children (1-12 years) - **Indication**: CFALD, other cholestatic liver diseases (off-label) - **Dose**: **20 mg/kg/day** for CFALD; **10-15 mg/kg/day** for other cholestasis. - **Frequency**: Divided into **2-3 doses daily** - **Maximum**: **20 mg/kg/day** for CFALD, **15 mg/kg/day** for other indications. ### Adolescents (13-18 years) - **Indication**: PBC, gallstones, CFALD, other cholestasis - **Dose**: Adult dosing based on weight and indication. - **Maximum**: **15-20 mg/kg/day** depending on indication. ## Safety Information ### Contraindications - **Absolute**: Complete biliary obstruction - **Absolute**: Acute cholecystitis or cholangitis - **Absolute**: Calcified cholesterol gallstones or pigment gallstones - **Absolute**: Non-functioning gallbladder - **Absolute**: Gallstone pancreatitis - **Relative**: Frequent episodes of biliary colic ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea - **Common (1-10%)**: Abdominal pain, nausea, constipation, dyspepsia, headache, pruritus (can be exacerbated initially), rash. - **Serious but Rare**: Worsening of pre-existing liver disease (especially decompensated cirrhosis), allergic reactions. ### Key Drug Interactions - **Bile Acid Sequestrants (Cholestyramine, Colestipol)**: Reduce UDCA absorption. Administer UDCA **2 hours before or 4-6 hours after** sequestrants. - **Antacids (Aluminum-based)**: Reduce UDCA absorption. Separate by **2 hours**. - **Estrogens, Oral Contraceptives, Clofibrate**: May increase cholesterol secretion into bile, potentially counteracting UDCA. - **Ciclosporin**: UDCA may increase ciclosporin absorption and blood levels. **Monitor ciclosporin levels** and adjust dose as needed. ## Monitoring & Follow-up - **Before Treatment**: Baseline liver function tests (ALT, AST, ALP, GGT, total bilirubin), serum albumin, INR, abdominal ultrasound (for gallstones). - **During Treatment**: - **LFTs**: Every **1-3 months** for the first 6 months, then every **6-12 months** or as clinically indicated. - **Ultrasound**: Every **6-12 months** for gallstone dissolution, or annually for PBC/CFALD. - **Clinical Signs**: Monitor for worsening pruritus, jaundice, new or worsening abdominal pain, or other signs of liver decompensation. ## Clinical Pearls - 💡 **Tip 1**: Take UDCA with food to enhance absorption and minimize gastrointestinal side effects. - 💡 **Tip 2**: Gallstone dissolution is a slow process; treatment usually requires **6 to 24 months** and is not effective for calcified stones. - 💡 **Tip 3**: UDCA therapy for PBC is generally lifelong once initiated to maintain liver health. - 💡 **Tip 4**: For ICP, UDCA should be continued until delivery for optimal maternal and fetal outcomes. - 💡 **Tip 5**: Ensure patient compliance, especially in chronic conditions, as missed doses can reduce efficacy. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.